Novo Nordisk A/S/€NOVOB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.
Ticker
€NOVOB
Sector
Primary listing
XGAT
Employees
78,387
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk A/S Metrics
BasicAdvanced
€214B
14.43
€3.34
0.27
€1.56
3.24%
Price and volume
Market cap
€214B
Beta
0.27
52-week high
€123.22
52-week low
€38.56
Average daily volume
561K
Dividend rate
€1.56
Financial strength
Current ratio
0.784
Quick ratio
0.505
Long term debt to equity
51.947
Total debt to equity
59.065
Dividend payout ratio (TTM)
45.63%
Interest coverage (TTM)
17.27%
Profitability
EBITDA (TTM)
21,334.604
Gross margin (TTM)
84.26%
Net profit margin (TTM)
35.61%
Operating margin (TTM)
47.65%
Effective tax rate (TTM)
21.10%
Revenue per employee (TTM)
€533,160
Management effectiveness
Return on assets (TTM)
21.82%
Return on equity (TTM)
79.17%
Valuation
Price to earnings (TTM)
14.427
Price to revenue (TTM)
5.132
Price to book
9.49
Price to tangible book (TTM)
26.51
Price to free cash flow (TTM)
25.988
Free cash flow yield (TTM)
3.85%
Free cash flow per share (TTM)
1.856
Dividend yield (TTM)
3.24%
Growth
Revenue change (TTM)
20.90%
Earnings per share change (TTM)
24.26%
3-year revenue growth (CAGR)
25.65%
10-year revenue growth (CAGR)
12.15%
3-year earnings per share growth (CAGR)
31.20%
10-year earnings per share growth (CAGR)
15.33%
3-year dividend per share growth (CAGR)
27.85%
10-year dividend per share growth (CAGR)
16.64%
Bulls say / Bears say
Partnership with Replicate Bioscience to develop obesity, type 2 diabetes, and cardiometabolic therapies using self-replicating RNA technology bolsters Novo Nordisk’s early-stage pipeline. (Reuters)
Collaboration and licensing deal with Septerna worth up to $2.2 billion to develop oral small molecule treatments diversifies Novo Nordisk’s modality mix beyond injectables. (Reuters)
Licensing of Lexicon’s experimental obesity drug LX9851 in a deal valued up to $1 billion broadens Novo Nordisk’s future obesity management product pipeline. (Reuters)
Lowered 2025 sales growth guidance to 8–14% from 13–21% triggered a $70 billion market cap loss and near 30% share drop, reflecting investor concerns over growth sustainability. (Reuters)
Intensified competition from Eli Lilly’s Zepbound and unregulated compounded GLP-1 copies precipitated market share losses in the U.S., leading Denmark to halve its 2025 GDP forecast due in part to Novo Nordisk weakness. (Reuters)
Recent cost-cutting initiatives and a sudden CEO replacement amid underwhelming revenue performance underscore operational pressures and could weigh on strategic execution. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk A/S stock?
Novo Nordisk A/S (NOVOB) has a market cap of €214B as of September 17, 2025.
What is the P/E ratio for Novo Nordisk A/S stock?
The price to earnings (P/E) ratio for Novo Nordisk A/S (NOVOB) stock is 14.43 as of September 17, 2025.
Does Novo Nordisk A/S stock pay dividends?
Yes, the Novo Nordisk A/S (NOVOB) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is €1.56116 and the yield is 3.24%. Novo Nordisk A/S has a payout ratio of 45.63% on a trailing twelve-month basis.
When is the next Novo Nordisk A/S dividend payment date?
The next Novo Nordisk A/S (NOVOB) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk A/S?
Novo Nordisk A/S (NOVOB) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.